Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam plus nalbuphine versus propofol for painless hysteroscopy
ChiCTR2200057416Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Apr 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam, nalbuphine and propofol in None (3 arms), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoints: Onset time, Duration time given initial dose and 6 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
remimazolamnalbuphinepropofol
Beyond the preview
Go deeper on ChiCTR2200057416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057416.